Lurbinectedin as a Second-line Treatment for High-grade Pancreatic Neuroendocrine Tumors Under Clinical Trial

Strategic Insights -

Researchers at the National Cancer Center, Korea, are conducting a Phase 2 clinical trial to study the efficacy of lurbinectedin as a second-line treatment for high-grade pancreatic neuroendocrine tumors (pNETs). The trial aims to enroll 46 participants from the USA and is currently active but not open for recruiting. The principal investigator is Sang Myung Woo, MD, and the study is being conducted in collaboration with several leading hospitals in Korea.

Key Takeaways:

  • The trial focuses on evaluating lurbinectedin as a second-line treatment for high-grade pNETs, which are rare and aggressive forms of cancer.
  • Current treatment options for pNETs include hormonal therapy, targeted therapy, and cytotoxic chemotherapy, but a standard of care remains to be established.
  • The trial aims to investigate the efficacy of lurbinectedin in comparison to existing treatments such as cisplatin/etoposide, FOLFIRI, and temozolomide ± capecitabine.
  • The study is being conducted at the National Cancer Center, Korea, and is collaborating with Seoul National University Bundang Hospital, Samsung Medical Center, Seoul National Hospital, and Gangnam Severance Hospital.
  • Sang Myung Woo, MD, is the principal investigator of the trial.

Statistics:

  • The trial aims to enroll 46 participants from the USA.
  • The study is currently active but not open for recruiting.
  • High-grade pNETs are a rare form of cancer, and the trial aims to investigate the efficacy of lurbinectedin in treating this aggressive form of cancer.
  • Current treatment options for pNETs have limitations, and a standard of care remains to be established.

Sources:

  • ClinicalTrials.gov
  • National Cancer Center, Korea